Suppr超能文献

PCSK9 Inhibitors and Cardiovascular Events.

作者信息

Auer Johann, Berent Robert, Primus Carina

出版信息

N Engl J Med. 2015 Aug 20;373(8):773. doi: 10.1056/NEJMc1508222.

Abstract
摘要

相似文献

1
PCSK9 Inhibitors and Cardiovascular Events.
N Engl J Med. 2015 Aug 20;373(8):773. doi: 10.1056/NEJMc1508222.
2
PCSK9 Inhibitors and Cardiovascular Events.
N Engl J Med. 2015 Aug 20;373(8):774. doi: 10.1056/NEJMc1508222.
3
PCSK9 Inhibitors and Cardiovascular Events.
N Engl J Med. 2015 Aug 20;373(8):774-5. doi: 10.1056/NEJMc1508222.
4
PCSK9 Inhibitors and Cardiovascular Events.
N Engl J Med. 2015 Aug 20;373(8):773-4. doi: 10.1056/NEJMc1508222.
5
PCSK9 inhibitors reduce cardiovascular events, preliminary data show.
BMJ. 2015 Mar 17;350:h1508. doi: 10.1136/bmj.h1508.
6
Lowering LDL cholesterol is good, but how and in whom?
N Engl J Med. 2015 Apr 16;372(16):1564-5. doi: 10.1056/NEJMe1502192. Epub 2015 Mar 15.
7
Dyslipidaemia. Assessing the efficacy and safety of evolocumab and alirocumab.
Nat Rev Cardiol. 2015 May;12(5):261. doi: 10.1038/nrcardio.2015.51. Epub 2015 Mar 31.
8
PCSK9 inhibition: the next statin?
J Am Coll Cardiol. 2012 Jun 19;59(25):2354-5. doi: 10.1016/j.jacc.2012.03.011. Epub 2012 Mar 31.
10
Efficacy and safety of alirocumab in reducing lipids and cardiovascular events.
N Engl J Med. 2015 Apr 16;372(16):1489-99. doi: 10.1056/NEJMoa1501031. Epub 2015 Mar 15.

引用本文的文献

1
Alirocumab as add-on therapy to statins: current evidence and clinical potential.
Ther Adv Cardiovasc Dis. 2018 Jul;12(7):191-202. doi: 10.1177/1753944718775352. Epub 2018 May 24.
2
A Systematic Review of PCSK9 Inhibitors Alirocumab and Evolocumab.
J Manag Care Spec Pharm. 2016 Jun;22(6):641-653q. doi: 10.18553/jmcp.2016.22.6.641.
3
PCSK9 inhibitors and cardiovascular disease: heralding a new therapeutic era.
Curr Opin Lipidol. 2015 Dec;26(6):511-20. doi: 10.1097/MOL.0000000000000239.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验